使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Intuitive Surgical Q4 2012 earnings release call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions).
各位女士、先生,感謝您稍候。歡迎參加直覺外科(Intuitive Surgical)2012 年第四季財報發布電話會議。目前所有與會者皆為僅收聽模式。稍後我們將進行問答環節,屆時會提供相關指示。(接線員指示)。
As a reminder this conference is being recorded. I will now turn the conference over to Calvin Darling, Senior Director of Finance for Intuitive Surgical. Please go ahead.
提醒各位,本次會議將被錄音。現在我將把會議交給直覺外科財務資深總監 Calvin Darling。請開始。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Thank you. Good afternoon and welcome to Intuitive Surgical's fourth-quarter earnings conference call. With me today we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Aleks Cukic, our Vice President of Strategic Planning.
謝謝。各位下午好,歡迎參加直覺外科第四季財報電話會議。今天與我一同出席的有:總裁暨執行長 Gary Guthart;財務長 Marshall Mohr;以及策略規劃副總裁 Aleks Cukic。
Before we begin I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described (technical difficulty) detail in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. Please note that this conference call will be available for audio replay on our website at IntuitiveSurgical.com on the audio archive section under our investor relations page.
在開始之前,我想提醒各位,今天電話會議中提及的評論可能被視為包含前瞻性陳述。由於若干風險與不確定性,實際結果可能與明示或暗示的內容有重大差異。這些風險與不確定性已在公司向美國證券交易委員會(SEC)提交的文件中(技術問題)詳細說明。提醒潛在投資人勿過度依賴此類前瞻性陳述。請注意,本次電話會議的錄音回放將可於我們網站 IntuitiveSurgical.com 的投資人關係頁面之音訊存檔區收聽。
In addition, today's press release has been posted to our website. Today's format will consist of providing you with highlights of our fourth-quarter results as described in our press release announced earlier today, followed by a question-and-answer session.
此外,今天的新聞稿已發布於我們的網站。今天的流程將先提供我們第四季業績重點(如稍早發布之新聞稿所述),接著進行問答環節。
Gary will present the quarter's business and operational highlights. Marshall will provide a review of our fourth-quarter financial results. Aleks will discuss marketing and clinical highlights. Then I will provide our financial forecast for 2013. And, finally, we will host a question-and-answer session.
Gary 將說明本季的業務與營運重點。Marshall 將回顧我們第四季的財務結果。Aleks 將討論行銷與臨床重點。接著我將提供我們 2013 年的財務預測。最後,我們將進行問答環節。
With that I will turn it over to Gary.
接下來我把時間交給 Gary。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Thank you for joining us on the call today. 2012 has been a productive year at Intuitive. In the past year our focus was in the following four areas. First, continued growth in gynecology and urology worldwide. Second, disciplined execution of our Single-Site and Vessel Sealing launches.
感謝各位今天加入本次電話會議。2012 年對直覺外科而言是富有成果的一年。過去一年我們的重點聚焦在以下四個領域。第一,持續推動婦科與泌尿科在全球的成長。第二,有紀律地執行我們 Single-Site(單孔)與 Vessel Sealing(血管封合)產品上市。
Third, building robust clinical programs with leading customers in emerging procedures in general surgery, thoracic surgery and transoral surgery. And, finally, strengthening our capabilities in international markets.
第三,與領先客戶共同建立強健的臨床計畫,推動一般外科、胸腔外科與經口手術等新興術式。最後,強化我們在國際市場的能力。
In reviewing the year, I will turn first to procedures. Year-over-year growth in procedures finished at 25%, led by continued uptake in gynecology and growing use of da Vinci in General Surgery. Gynecology growth was broad-based with increased use of da Vinci Surgery for gynecologic oncology, hysterectomy, myomectomy, and sacrocolpopexy.
回顧本年度,我將先從手術量談起。手術量年增率達 25%,主要由婦科持續採用以及達文西在一般外科的使用增加所帶動。婦科成長面向廣泛,達文西手術在婦科腫瘤、子宮切除術、子宮肌瘤切除術以及薦骨陰道固定術(sacrocolpopexy)的使用均有所增加。
General Surgery growth was substantial in the year, led by increased use of da Vinci in colorectal procedures and cholecystectomy, the latter driven by interest in da Vinci Single-Site.
一般外科在本年度的成長相當顯著,主要由達文西在大腸直腸手術與膽囊切除術的使用增加所帶動;其中後者的成長來自市場對達文西 Single-Site 的興趣。
Globally urology as a category was up slightly for the year, pressured by a significant reduction in prostatectomies in the United States. As we have mentioned on prior calls, we believe the reduction in prostatectomies is the result of a combination of factors including recommendations moving away from the use of PSA testing for early detection, and an increase in non-definitive treatment pathways such as watchful waiting.
就全球而言,泌尿科作為一個類別在本年度僅小幅成長,主要受到美國前列腺切除術大幅減少的壓力。如同我們在先前電話會議中提到的,我們認為前列腺切除術的減少是多項因素共同造成,包括建議逐步減少使用 PSA 檢測作為早期篩檢,以及採用更多非根治性治療途徑(例如觀察等待)。
However, we did see a quarterly sequential rise in the United States in prostatectomies from the third quarter to the fourth quarter of 2012. Aleks will take you through greater detail on our procedure performance later in the call.
不過,我們確實看到 2012 年美國前列腺切除術在季度上由第三季到第四季呈現連續上升。稍後在本次電話會議中,Aleks 將就我們的手術量表現提供更詳細的說明。
Turning to da Vinci Surgery outside of the United States, in 2012 we focused on improving our performance in Asia and in Europe. In Japan reimbursement approval for da Vinci Prostatectomy contributed to significant early uptake of systems and procedures.
談到美國以外的達文西手術,2012 年我們著重於提升在亞洲與歐洲的表現。在日本,達文西前列腺切除術獲得健保給付核准,帶動系統與手術量在初期顯著採用。
In the fourth quarter, we received clearance for our da Vinci Si system in Japan, and customer shipments for Si are planned to commence in this first quarter of 2013. We expect progress in Japan to proceed in steps as we pursue additional instrument regulatory clearances and additional procedure reimbursement.
在第四季,我們的達文西 Si 系統在日本取得核准,並計畫於 2013 年第一季開始向客戶出貨 Si。我們預期日本的進展將以階段性方式推進,因為我們將持續爭取更多器械的法規核准以及更多術式的給付。
In Europe we made progress in the fourth quarter, seeing a significant increase in System sales as we invested in deepening our organization. However, per our commentary through the year, we have more work to do in building our organization to perform in a challenging environment. We expect these challenges in Europe and our investments to continue for the next several quarters.
在歐洲,我們於第四季取得進展;隨著我們加大投入以深化組織,系統銷售顯著增加。然而,正如我們全年所述,在充滿挑戰的環境中打造能夠有效運作的組織,我們仍有更多工作要做。我們預期歐洲的這些挑戰以及我們的投資將在未來數季持續。
Our product launch has proceeded well in 2012. Response to our da Vinci Vessel Sealer and Single-Site instrument kit was positive in the year with over 450 Si customers purchasing Single-Site starter kits. Surgeon acceptance of Vessel Sealer has been encouraging with Vessel Sealer use focused on colorectal surgeons as well as GYN oncologists.
我們在 2012 年的產品上市進展順利。本年度市場對達文西血管封合器(Vessel Sealer)與 Single-Site 器械套件的反應正面,超過 450 位 Si 客戶購買了 Single-Site 入門套件。外科醫師對 Vessel Sealer 的接受度令人鼓舞,其使用主要集中在大腸直腸外科醫師以及婦科腫瘤醫師。
We received 510(k) clearance in the United States for our da Vinci stapler and we plan to start a controlled rollout over the next several weeks. Our rollout this year for our stapler will be carefully phased and focused on excellent customer experiences.
我們在美國取得達文西縫合釘器(stapler)的 510(k) 核准,並計畫在未來幾週開始受控式推廣。今年我們對縫合釘器的推廣將謹慎分階段進行,並以提供卓越的客戶體驗為重點。
For our prior calls, in Q3 of 2012 we submitted a 510(k) for an additional set of instruments and an extended indication for Single-Site for use in hysterectomy and oophorectomy. Our dialogue with FDA on this kit has been constructive.
如同先前電話會議所述,2012 年第三季我們提交了一項 510(k),涵蓋一組額外器械,並將 Single-Site 的適應症擴展至子宮切除術與卵巢切除術。我們與 FDA 就此套件的溝通具建設性。
In imaging we submitted a 510(k) application to expand indications for our Firefly fluorescence imaging system to use in biliary imaging. We believe this will have application for use in imaging the common bile duct during cholecystectomy and will complement the use of Single-Site.
在影像方面,我們提交了一項 510(k) 申請,將 Firefly 螢光影像系統的適應症擴展至膽道影像。我們相信這將可用於在膽囊切除術中對總膽管進行成像,並可與 Single-Site 的使用相互補強。
Looking back at the full year 2012, our operating highlights are as follows. Worldwide procedures grew by approximately 25%. We sold 620 da Vinci Surgical Systems in the year, up from 534.
回顧 2012 全年,我們的營運重點如下。全球手術量約成長 25%。全年我們售出 620 套達文西手術系統,高於前一年的 534 套。
Total revenue grew to $2.178 billion, up 24% over 2011. Recurring revenue grew to $1.246 billion, up 27% and comprising 57% of total revenue.
總營收成長至 21.78 億美元,較 2011 年增加 24%。經常性收入成長至 12.46 億美元,增加 27%,並占總營收的 57%。
We generated $1.031 billion in operating profit before non-cash stock compensation expense, up 24% from last year. And GAAP net income grew to $657 million, up 33% year-over-year.
我們在扣除非現金股票薪酬費用前的營業利益為 10.31 億美元,較去年成長 24%。依 GAAP 計算的淨利成長至 6.57 億美元,年增 33%。
Turning to operating highlights for the fourth quarter, procedures grew approximately 25% over the fourth quarter of last year. We sold 175 da Vinci surgical systems, up from 152 in the fourth quarter of 2011.
談到第四季的營運重點,手術量較去年第四季約成長 25%。我們售出 175 套達文西手術系統,高於 2011 年第四季的 152 套。
Total revenue for the quarter was $609 million, up 23% from the fourth quarter of 2011. Instrument and accessory revenue increased to $254 million, up 29%.
本季總營收為 6.09 億美元,較 2011 年第四季成長 23%。器械與配件營收增加至 2.54 億美元,成長 29%。
We generated an operating profit of $286 million in the quarter before non-cash stock compensation expense, up 22% from the fourth quarter of last year. And GAAP net income grew to $175 million, up 16%.
本季我們在扣除非現金股票薪酬費用前的營業利益為 2.86 億美元,較去年第四季成長 22%。依 GAAP 計算的淨利成長至 1.75 億美元,成長 16%。
We ended the year with $2.921 billion in cash and investments, up $219 million from last quarter and up $749 million from last year. We received $263 million in cash during the year from the exercise of stock options and invested $180 million in intellectual property; working capital; property, plant and equipment; and $238 million in stock repurchases for the year.
我們在年底的現金及投資為29.21億美元,較上季增加2.19億美元,較去年增加7.49億美元。本年度我們因員工行使股票選擇權收到2.63億美元現金,並投資1.80億美元於智慧財產權、營運資金、廠房及設備;且本年度用於股票回購為2.38億美元。
In the quarter we added 170 people to our team, predominantly in our clinical sales force, our manufacturing team and design functions in Q4, bringing our total team to 2362 employees.
本季我們的團隊新增170人,主要加入我們的臨床銷售團隊、製造團隊以及第四季的設計職能,使員工總數達到2,362人。
Looking to 2013 our priorities are as follows. First, continued focus on use of da Vinci in gynecology. Second, supporting emerging growth of da Vinci in General Surgery. Third, disciplined execution of our stapling and Single-Site for hysterectomy launches, focused and outstanding early customer experiences. And, finally, continuing to strengthen our capabilities in international markets, particularly Europe and Japan.
展望2013年,我們的優先事項如下。第一,持續聚焦於達文西在婦科的使用。第二,支持達文西在一般外科的新興成長。第三,有紀律地執行我們的縫合器與子宮切除術Single-Site上市計畫,聚焦並提供卓越的早期客戶體驗。最後,持續強化我們在國際市場的能力,特別是歐洲與日本。
I will now pass the time over to Marshall Mohr, our Chief Financial Officer, to take us through our financial performance in greater detail.
接下來我把時間交給我們的財務長Marshall Mohr,請他更詳細地帶領大家了解我們的財務表現。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Thank you, Gary. Our fourth-quarter revenue was $609 million, up 23% compared with $497 million for the fourth quarter of 2011 and up 13% compared with $538 million last quarter.
謝謝你,Gary。我們第四季營收為6.09億美元,較2011年第四季的4.97億美元成長23%,較上季的5.38億美元成長13%。
Fourth-quarter revenues by product category were as follows. Fourth-quarter instrument and accessory revenue was $254 million, up 29% compared with $196 million in the fourth quarter of 2011, and up 16% compared with $218 million in the third quarter of 2012.
第四季按產品類別的營收如下。第四季器械與配件營收為2.54億美元,較2011年第四季的1.96億美元成長29%,較2012年第三季的2.18億美元成長16%。
The year-over-year increase in I&A was driven by procedure growth of approximately 25%; sales of new instrument and accessory products including Single-Site, Vessel Sealer, and Firefly; and higher stocking orders associated with higher system unit sales. The year-over-year procedure growth was led by US gynecology and general surgery procedures, partially offset by lower growth in Europe and a year-over-year decrease in US DVPs of approximately 17%.
器械與配件(I&A)年增的主因為手術量約成長25%;新器械與配件產品(包括Single-Site、Vessel Sealer與Firefly)的銷售;以及因系統銷售台數增加而帶動的較高初始備貨訂單。年增的手術量成長主要由美國婦科與一般外科手術帶動,但部分被歐洲較低的成長以及美國DVP年減約17%所抵銷。
The sequential increase in I&A revenue compared with the last quarter was driven by higher procedure volume benefiting from favorable fourth-quarter seasonality of benign procedures, higher new product sales, higher initial stocking orders and the timing of distributor orders. Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $2050 per procedure, which is higher than the $1980 realized in the fourth quarter of 2011 and the third quarter of 2012.
與上季相比,I&A營收的季增主要來自手術量提高(受惠於第四季良性手術的有利季節性)、新產品銷售增加、初始備貨訂單增加,以及經銷商訂單時點的影響。每例手術實現的器械與配件營收(含初始備貨訂單)約為每例2,050美元,高於2011年第四季與2012年第三季的每例1,980美元。
The sequential year-over-year increases were driven by higher new product sales, including Vessel Sealers, Single-Site kits and Firefly kits; higher initial stocking orders associated with higher systems unit sales; and the timing of distributor orders.
上述連續的年增幅主要由新產品銷售增加所帶動,包括Vessel Sealer、Single-Site套件與Firefly套件;因系統銷售台數增加而帶動的較高初始備貨訂單;以及經銷商訂單時點的影響。
Fourth quarter 2012 systems revenue of $265 million increased 18% compared with $225 million for the fourth quarter of 2011, and increased 14% compared with $232 million for the third quarter of 2012. We sold 175 systems in the fourth quarter of 2012 compared with 152 systems in the fourth quarter of 2011 and 155 systems in the third quarter of 2012.
2012年第四季系統營收為2.65億美元,較2011年第四季的2.25億美元成長18%,較2012年第三季的2.32億美元成長14%。2012年第四季我們售出175套系統,較2011年第四季的152套以及2012年第三季的155套為高。
Fourth quarter average sales price per system was $1.49 million, slightly above the $1.47 million realized in the fourth quarter of 2011, and the $1.48 million realized last quarter. ASPs include all da Vinci models, all simulators, and Firefly when configured with a system, and exclude upgrades. Fourth quarter ASPs benefited from a favorable mix of dual console systems, Firefly-enabled systems and direct sales to Europe.
第四季每套系統平均售價為149萬美元,略高於2011年第四季的147萬美元,以及上季的148萬美元。平均售價(ASP)包含所有達文西機型、所有模擬器,以及與系統一同配置時的Firefly,並不包含升級。第四季ASP受惠於雙主控台系統、具Firefly功能系統以及對歐洲的直銷占比較佳的產品組合。
ASPs will fluctuate quarter to quarter based on product, customer and trade-in mix, as well as foreign exchange rates on direct sales to international customers.
ASP將隨季度因產品、客戶與以舊換新組合,以及對國際客戶直銷的外匯匯率而波動。
We sold 115 simulators during the quarter, mostly in conjunction with new system sales, compared with 123 last year and 87 last quarter. We sold 32 dual console systems compared with 29 last year and 20 last quarter.
本季我們售出115台模擬器,多數與新系統銷售一併出售;相較之下,去年為123台,上季為87台。我們售出32套雙主控台系統,去年為29套,上季為20套。
52 of our fourth-quarter 2012 system sales involved trade-ins, comprised of 40 da Vinci S's and 12 standard models. 50 of our fourth-quarter 2011 sales involved trade-ins and 34 of our third quarter 2012 sales involved trade-ins.
2012年第四季我們的系統銷售中有52套涉及以舊換新,其中包括40套達文西S與12套標準機型。2011年第四季有50套銷售涉及以舊換新,而2012年第三季有34套銷售涉及以舊換新。
Service revenue increased to $91 million, up 20% compared with $75 million last year, and up 3% compared with $88 million last quarter. The growth in service revenue was primarily driven by a larger system installed base.
服務營收增至9,100萬美元,較去年7,500萬美元成長20%,較上季8,800萬美元成長3%。服務營收成長主要由更大的系統裝機基數所帶動。
Total fourth quarter recurring revenue -- comprised of instrument, accessory and service revenue -- increased to $344 million, up 27% compared with the fourth quarter of 2011 and up 13% compared with the third quarter of 2012. Recurring revenue represents 57% of total fourth-quarter revenue compared with 55% in the fourth quarter last year and 57% last quarter.
第四季經常性營收總額(由器械、配件與服務營收構成)增至3.44億美元,較2011年第四季成長27%,較2012年第三季成長13%。經常性營收占第四季總營收的57%,相較之下去年第四季為55%,上季為57%。
International revenue results were as follows. Fourth-quarter revenue outside the US was $131 million, up 23% compared with revenue of $107 million in the fourth quarter 2011, and up 14% compared with revenue of $115 million in the third quarter 2012. Our year-over-year and quarter-over-quarter international revenue growth was driven by increased procedures and higher system revenue.
國際營收結果如下。第四季美國以外營收為1.31億美元,較2011年第四季的1.07億美元成長23%,較2012年第三季的1.15億美元成長14%。我們國際營收的年增與季增主要由手術量增加以及系統營收提高所帶動。
Fourth-quarter 2012 international procedure volume was approximately 21% higher than the fourth quarter of 2011 and 15% higher than the seasonally slower third quarter of 2012. During the fourth quarter of 2012 we sold 42 systems outside the US compared with 39 in the fourth quarter of 2011 and 41 last quarter. We sold 24 systems in Europe this quarter compared with 23 in the fourth quarter of 2011 and 13 last quarter.
2012年第四季國際手術量約較2011年第四季高21%,較季節性較慢的2012年第三季高15%。2012年第四季我們在美國以外售出42套系統,2011年第四季為39套,上季為41套。本季我們在歐洲售出24套系統,2011年第四季為23套,上季為13套。
We sold 10 systems into Japan this quarter compared with five last year and 16 last quarter. A higher mix of systems to direct customers in Europe also contributed to higher system revenue in the fourth quarter of 2012 compared with the third quarter -- and the fourth quarter of 2011. Aleks will provide additional details of international system sales.
本季我們在日本售出10套系統,去年為5套,上季為16套。對歐洲直客的系統銷售占比較高,也促成2012年第四季系統營收較第三季以及2011年第四季更高。Aleks將提供更多國際系統銷售的細節。
Moving on to the remainder of the P&L, gross margin in the fourth quarter of 2012 was 71.9% compared with 73.1% during the fourth quarter of 2011 and 72.5% last quarter. Our lower year-over-year gross margin percentage resulted primarily from lower margins earned on our newer Single-Site and Vessel Sealer products. Our slight decline in margin percentage compared with the third quarter is mostly due to lower margins on a higher volume of our Vessel Sealer products.
接著看損益表其餘項目,2012年第四季毛利率為71.9%,相較2011年第四季為73.1%,上季為72.5%。我們毛利率年減主要是因較新的Single-Site與Vessel Sealer產品的毛利較低。相較第三季毛利率小幅下滑,主要是因Vessel Sealer產品銷量較高而其毛利較低所致。
Fourth-quarter 2012 operating expenses of $190 million were up 16% compared with the fourth quarter of 2011 and up 6% compared with the third quarter of 2012. Our higher fourth-quarter 2012 operating expenses were primarily driven by variable compensation associated with our higher fourth-quarter revenue and headcount additions.
2012年第四季營業費用為1.90億美元,較2011年第四季成長16%,較2012年第三季成長6%。2012年第四季營業費用較高,主要是因第四季營收較高所帶動的變動薪酬,以及人力增加所致。
Fourth-quarter 2012 operating income was $248 million or 41% of sales compared with $200 million or 40% of sales for the fourth quarter 2011, and $211 million or 39% of sales for the third quarter of 2012. Fourth-quarter 2012 operating income reflected $38 million of non-cash stock compensation expense compared with $35 million for the fourth quarter of 2011 and $47 million last quarter.
2012年第四季營業利益為2.48億美元,占銷售額41%;相較之下,2011年第四季為2.00億美元,占銷售額40%,2012年第三季為2.11億美元,占銷售額39%。2012年第四季營業利益包含3,800萬美元的非現金股票酬勞費用,相較之下2011年第四季為3,500萬美元,上季為4,700萬美元。
Our effective tax rate for the fourth quarter was 31% compared with 26% for the fourth quarter of 2011 and 15% last quarter. I want to remind you that the third quarter of 2012 tax rate of 15% included discrete tax benefits of $38 million associated with the expiration of the statute of limitations.
我們第四季的有效稅率為 31%,相較於 2011 年第四季的 26% 以及上一季的 15%。我想提醒各位,2012 年第三季 15% 的稅率包含了 3,800 萬美元的一次性稅務利益,與追溯時效(statute of limitations)到期相關。
The fourth quarter 2011 rate of 26% reflected the federal -- a federal R&D credit and discrete benefits associated with state tax returns. Our fourth-quarter 2012 rate of 31% is in line with our expectations and excluded the impact of the federal R&D credit reinstatement, which was enacted in 2013 and will be reflected as a discrete item in the first quarter of 2013.
2011 年第四季 26% 的稅率反映了聯邦——一項聯邦研發(R&D)稅額抵免,以及與州稅申報相關的一次性利益。我們 2012 年第四季 31% 的稅率符合預期,且未納入聯邦研發稅額抵免恢復的影響;該法案於 2013 年通過,並將在 2013 年第一季以一次性項目反映。
We estimate the R&D tax credit benefit for 2012 will be between $6 million and $8 million.
我們估計 2012 年研發稅額抵免的利益將介於 600 萬至 800 萬美元之間。
Our net income was $175 million or $4.25 per share compared with $151 million or $3.75 per share for the fourth quarter of 2011, and $183 million or $4.46 per share for the third quarter of 2012. Excluding the third quarter discrete tax benefits of $38 million, our third quarter net income would have been $145 million or $3.54 per share.
我們的淨利為 1.75 億美元(每股 4.25 美元),相較於 2011 年第四季的 1.51 億美元(每股 3.75 美元),以及 2012 年第三季的 1.83 億美元(每股 4.46 美元)。若排除第三季 3,800 萬美元的一次性稅務利益,我們第三季淨利將為 1.45 億美元(每股 3.54 美元)。
Let me quickly summarize our results for the full year of 2012. Procedures grew by 25% to approximately 450,000. Total revenue was $2.179 billion, up 24% compared with $1.757 billion last year. The revenue increase included recurring revenue growth of 27% and an increase in systems revenue of 20%.
我快速總結一下我們 2012 年全年的業績。手術量成長 25%,至約 45 萬例。總營收為 21.79 億美元,較去年的 17.57 億美元成長 24%。營收增加包含經常性營收成長 27%,以及系統營收成長 20%。
Full-year operating income was $878 million, up 26% compared with $695 million last year. Operating income included $153 million of stock-based compensation charges compared with $136 million in 2011.
全年營業利益為 8.78 億美元,較去年的 6.95 億美元成長 26%。營業利益包含 1.53 億美元的股票基礎報酬費用,2011 年為 1.36 億美元。
Net income was $657 million or $15.94(sic-see press release "$15.98") per share compared with $495 million or $12.32 per share last year. 2012 net income included approximately $46 million associated with statute of limitations and a change in rules for 199 tax credit. Excluding these items net income would have been $610 million or $14.85 per share.
淨利為 6.57 億美元(每股 15.94 美元(原文誤植—見新聞稿「15.98 美元」)),相較於去年的 4.95 億美元(每股 12.32 美元)。2012 年淨利包含約 4,600 萬美元,與追溯時效以及第 199 條稅額抵免規則變更相關。若排除這些項目,淨利將為 6.10 億美元(每股 14.85 美元)。
Year-to-date cash flow from operations was $814 million compared with $678 million last year.
年初至今的營運活動現金流為 8.14 億美元,去年為 6.78 億美元。
Now, moving on to cash flows, we ended the fourth quarter with cash and investments up $2.9 billion, up $220 million compared with September 30, 2012. The increase was driven by $217 million of cash flows from operations plus $87 million from the exercise of stock options, partially offset by a $53 million in stock buybacks and $61 million of capital and IP purchases. We bought back 102,000 shares at an average price of $524 per share and we have [330 million] forward authorized buybacks remaining.
接著談現金流:我們在第四季末的現金及投資為 29 億美元,較 2012 年 9 月 30 日增加 2.2 億美元。增加主要來自 2.17 億美元的營運活動現金流,加上 8,700 萬美元的員工行使股票選擇權所得;部分被 5,300 萬美元的庫藏股回購以及 6,100 萬美元的資本支出與智慧財產(IP)購置所抵銷。我們以每股平均 524 美元回購 102,000 股,且尚有 [3.30 億美元] 的遠期已核准回購額度。
And with that I would like to turn it over to Aleks, who will go over our sales, marketing and clinical highlights.
接下來我想把時間交給 Aleks,他將說明我們的銷售、行銷與臨床重點。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
Thank you, Marshall. During the fourth quarter we sold 175 da Vinci systems -- 133 in the United States, 24 into Europe and 18 into rest of world markets. As part of the 175 system sales, 12 standard da Vinci systems and 40 da Vinci S systems were traded in for credit against sales for new da Vinci Si systems.
謝謝你,Marshall。第四季我們售出 175 套達文西(da Vinci)系統——美國 133 套、歐洲 24 套、其他國際市場 18 套。在這 175 套系統銷售中,有 12 套標準達文西系統與 40 套達文西 S 系統以折抵方式換購新的達文西 Si 系統。
We had a net 123 system addition to the installed base during the quarter, which brings to 2585 the cumulative number of da Vinci systems worldwide -- 1878 in the United States, 416 in Europe, and 291 in rest of world markets. 114 of the 175 systems installed during the quarter represented repeat system sales to existing customers.
本季裝機基礎淨增加 123 套,使全球達文西系統累計達 2,585 套——美國 1,878 套、歐洲 416 套、其他國際市場 291 套。本季安裝的 175 套系統中,有 114 套為既有客戶的重複購買。
In total, 167 of the 175 systems sold represented da Vinci Si or Si-e systems which included 32 dual console systems. The 42 system sales internationally included 10 into Japan, four into Italy and three into the countries of Denmark, Switzerland and Canada.
總計而言,售出的 175 套系統中有 167 套為達文西 Si 或 Si-e 系統,其中包含 32 套雙控制台系統。國際市場的 42 套系統銷售中,包括日本 10 套、義大利 4 套,以及丹麥、瑞士與加拿大各 3 套。
Overall our da Vinci sales remained strong through the year totaling 620 systems.
整體而言,我們的達文西系統銷售全年維持強勁,合計達 620 套。
Clinically we finished the year strong, with Q4 year-over-year procedure growth of approximately 25%. The specialties of GYN in General Surgery were responsible for most of this growth.
臨床方面,我們以強勁表現結束全年,第四季手術量年增約 25%。其中婦科(GYN)與一般外科是成長的主要來源。
dVP, more specifically US dVP, a topic we have extensively discussed over the past several quarters, declined 17% on a Q4 over Q4 basis, but was up 2% on a sequential basis. While the rate of decline has tempered a bit, we are not in position to declare an endpoint to its decline.
dVP,尤其是美國 dVP——這是我們過去幾季廣泛討論的議題——以第四季對第四季比較下滑 17%,但按季比較則成長 2%。雖然下滑幅度稍有趨緩,但我們尚未能宣告其下滑已到終點。
Our fourth-quarter growth rate matched our 2012 overall procedure growth rate of 25%. US procedure growth for the year was approximately 26% as compared to 23% for our international markets. The specialties of GYN and general surgery contributed the overwhelming majority of 2012 procedure growth. The nine hysterectomy, cholecystectomy, colon and rectal recessions, endometriosis resection, partial nephrectomy and sacrocolpopexy were the largest individual contributors to procedure growth, which more than offset the decline within our 2012 US dVP business.
我們第四季的成長率與 2012 年整體手術量成長率 25% 相符。美國全年手術量成長約 26%,相較之下國際市場約為 23%。婦科與一般外科貢獻了 2012 年手術量成長的絕大部分。子宮切除術、膽囊切除術、結腸與直腸切除術、子宮內膜異位症切除、部分腎切除術以及薦骨陰道固定術(sacrocolpopexy)是手術量成長的最大單項貢獻者,且其增量足以抵銷我們 2012 年美國 dVP 業務的下滑。
The US procedure breakdown for 2012 was as follows. Total procedures grew to approximate 373,000, up from 292,000 in 2011. Total GYN grew to approximately 222,000 procedures, up from 170,000 in 2011.
2012 年美國手術量的組成如下。總手術量成長至約 373,000 例,高於 2011 年的 292,000 例。婦科(GYN)總手術量成長至約 222,000 例,高於 2011 年的 170,000 例。
DVH accounted for approximately 176,000 procedures, up from 140,000 in 2011. Urology accounted for approximately 88,000 procedures, which were down from approximately 93,000 in 2011. US dVP declined from approximately 73,000 to 62,000 procedures. General surgery procedures increased to approximately 42,000, up from 15,000 in 2011, representing a 173% increase.
DVH 約占 176,000 例手術,高於 2011 年的 140,000 例。泌尿科約占 88,000 例手術,低於 2011 年約 93,000 例。美國 dVP 由約 73,000 例下降至 62,000 例。一般外科手術增加至約 42,000 例,高於 2011 年的 15,000 例,增幅達 173%。
Recently released new products continue to do well, notably Single-Site. Early customer feedback has been positive, and our initial sales have been strong. Through the fourth quarter we have sold Single-Site instrument and accessory kits to approximately 450 US customers.
近期推出的新產品持續表現良好,尤其是 Single-Site。早期客戶回饋正面,我們的初期銷售也很強勁。截至第四季,我們已向約 450 位美國客戶銷售 Single-Site 器械與配件套組。
Our recently launched Vessel Sealer product continues to pick up clinical momentum, with most of the interest coming from colorectal, advanced general and GYN clinicians. The customer adoption for both da Vinci simulator and Firefly continues to expand with 115 customers purchasing a da Vinci simulator and 88 customers purchasing Firefly systems as part of their da Vinci purchase this quarter.
我們近期推出的 Vessel Sealer 產品持續累積臨床動能,興趣主要來自大腸直腸科、進階一般外科與婦科(GYN)臨床醫師。達文西模擬器(da Vinci simulator)與 Firefly 的客戶採用也持續擴大,本季有 115 位客戶購買達文西模擬器,另有 88 位客戶在購買達文西系統時一併購買 Firefly 系統。
During the quarter several hundred robotic abstracts and papers representing a variety of surgical specialties were published within various peer-reviewed journals. While quarterly clinical conferences produced several live da Vinci procedure transmissions, postgraduate robotic courses, podium presentations and clinical poster sessions.
本季有數百篇與機器人手術相關的摘要與論文在各類同儕審查期刊上發表,涵蓋多種外科專科。同時,季度臨床會議也進行了多場達文西手術的現場轉播、研究所後機器人課程、講台報告以及臨床海報展示。
Some of our early general surgery success is rooted within complex procedures which are often considered difficult to perform through traditional laparoscopic technique. Laparoscopic mid and low rectal cancer resections have, for years, proved challenging for even the most advanced laparoscopic surgeons, and as a result clinical adoption remains low.
我們在一般外科的部分早期成功,源自於一些複雜手術;這些手術通常被認為難以用傳統腹腔鏡技術完成。多年來,腹腔鏡中、低位直腸癌切除術即使對最先進的腹腔鏡外科醫師而言也具挑戰性,因此臨床採用率仍偏低。
The added benefit of da Vinci's articulated instrumentation, intuitive movement and magnified 3-D HD vision has provided a new foundation for MIS advancement in this field. A recent three-arm comparison of the Department of Surgery at Yonsei University College of Medicine was published in the Annals of Surgery. The study reported on pathological pathologic result, morbidity, perioperative, recovery and short-term oncologic results of 165 patients undergoing robotic, laparoscopic and open mid and low rectal cancer procedures.
達文西系統具關節式器械、直覺式操作與放大之 3-D HD 視覺所帶來的額外優勢,已為此領域微創手術(MIS)的進一步發展奠定了新的基礎。延世大學醫學院外科系近期發表了一項三組比較研究,刊登於《Annals of Surgery》。該研究報告了 165 名接受機器人、腹腔鏡及開腹之中低位直腸癌手術患者的病理結果、併發症發生率、圍手術期、復原情形與短期腫瘤學結果。
The findings from this case -- this case-matched study revealed that robotic surgery for the treatment of mid to low rectal cancer resulted in significant decreases in the amount of analgesia used, postoperative pain and length of stay. Although sphincter-preserving procedures were frequently performed with robotic surgery, the incidence of circumferential margin involvement and immediate postop voiding problems showed a significant decrease with robotic surgery as compared with open surgery. Robotic surgery showed better recovery outcomes than lap surgery with regard to time to resume soft diet and length of hospital stay.
此案例—此配對研究的結果顯示,針對中至低位直腸癌的機器人手術,可顯著降低止痛藥使用量、術後疼痛及住院天數。雖然機器人手術常進行保留括約肌的手術,但與開腹手術相比,機器人手術在環周切緣受累的發生率以及術後即刻排尿問題方面均顯著降低。就恢復軟質飲食時間與住院天數而言,機器人手術的復原結果優於腹腔鏡手術。
The visual analog scale was significantly lower in robotic surgery than in laparoscopic surgery and open surgery from postoperative days one through five. And no significant differences were found in two-year disease-free survival rates between the three groups, causing the authors to conclude, and I quote, robotic surgery may be an effective tool in the effort to maximize the advantages of minimally invasive surgery in the management of mid and low rectal cancers. Close quote.
從術後第 1 天至第 5 天,機器人手術的視覺類比量表(VAS)評分顯著低於腹腔鏡手術與開腹手術。此外,三組在兩年無病存活率方面未見顯著差異,因此作者結論(引述)為:機器人手術可能是管理中低位直腸癌時,最大化微創手術優勢的一項有效工具。引述完畢。
The clinical pursuit toward nephron-sparing kidney surgery has increased significantly over the past several years, with more and more urologists adopting partial nephrectomy. A 500-patient study out of the Cleveland Clinic entitled Comparative Outcomes and Assessment of Trifecta and 500 Robotic and Laparoscopic Partial Nephrectomies was published in the journal Urology. Trifecta is defined as a partial nephrectomy where warm ischemia time is kept below 25 minutes with negative surgical margins and no perioperative complications.
過去數年來,臨床上對腎單位保留(nephron-sparing)的腎臟手術追求顯著增加,越來越多泌尿科醫師採用部分腎切除術。克里夫蘭診所一項 500 名患者研究,題為《Comparative Outcomes and Assessment of Trifecta and 500 Robotic and Laparoscopic Partial Nephrectomies》,已發表於《Urology》期刊。「Trifecta」定義為:部分腎切除術中溫缺血時間控制在 25 分鐘以內、手術切緣陰性,且無圍手術期併發症。
The study reported that even with the more complex tumor profiles found in the da Vinci cohort, operating times were nearly 22 minutes less as compared to the laparoscopic cohort, 169 minutes versus 191 minutes.
研究指出,即使達文西組的腫瘤特徵更為複雜,其手術時間仍較腹腔鏡組縮短近 22 分鐘,分別為 169 分鐘對 191 分鐘。
Intra-operative complications associated with da Vinci patients were less than half when compared to laparoscopy, 2.6% as compared to 5.6%. Postoperative complications were 24.5% in the da Vinci cohort as compared to 32% for patients within the laparoscopic arm. Positive surgical margins were 2.9% in the da Vinci cohort as compared to 5.9% for laparoscopy.
與腹腔鏡相比,達文西患者的術中併發症不到其一半,為 2.6% 相較於 5.6%。術後併發症方面,達文西組為 24.5%,腹腔鏡組為 32%。陽性手術切緣方面,達文西組為 2.9%,腹腔鏡為 5.9%。
The overall trifecta rate was significantly higher in the da Vinci cohort at 58.7% as compared to 31.6% for the laparoscopic group. These findings led to the author's conclusion, and I quote, our large analysis shows that robotic partial nephrectomy offers a wider range of indications, better operative outcomes and lower perioperative morbidity compared to laparoscopic partial nephrectomy. Overall, the quest for trifecta seems to be better accomplished by robotic partial nephrectomy, thus likely to become the new standard technique for minimally invasive partial nephrectomy. Close quote.
整體 trifecta 達成率在達文西組顯著較高,為 58.7%,相較於腹腔鏡組的 31.6%。這些發現使作者結論(引述):我們的大型分析顯示,與腹腔鏡部分腎切除術相比,機器人部分腎切除術提供更廣泛的適應症範圍、更佳的手術結果以及較低的圍手術期罹病率。整體而言,追求 trifecta 似乎更能透過機器人部分腎切除術達成,因此很可能成為微創部分腎切除術的新標準技術。引述完畢。
Once again, the category of GYN contributed greater total procedure growth than any specialty we serve. Da Vinci sacrocolpopexy volume trails only da Vinci hysterectomy within this specialty and it continued its solid growth during the year.
再次強調,婦科(GYN)類別對我們所服務各專科中,貢獻了最大的總手術量成長。在此專科中,達文西薦骨陰道固定術(sacrocolpopexy)的手術量僅次於達文西子宮切除術,且今年持續穩健成長。
In a recent edition of Female Pelvic Medicine and Reconstructive Surgery, physicians from the University of South Florida reported the results of their 164-patient study comparing da Vinci sacrocolpopexy two open sacrocolpopexy. This retrospective study focused on cost, operative time and the length of stay for each group. Within this study, both system costs and maintenance costs were considered and included.
在近期一期《Female Pelvic Medicine and Reconstructive Surgery》中,南佛羅里達大學的醫師報告了其 164 名患者研究結果,比較達文西薦骨陰道固定術與開腹薦骨陰道固定術。此回溯性研究聚焦於各組的成本、手術時間與住院天數。研究中亦將系統成本與維護成本納入考量並計入。
The authors reported that the median operative time for open sacrocolpopexy and da Vinci sacrocolpopexy was 166 minutes and 212 minutes respectively. Estimated blood loss averaged 150 milliliters in the open sacrocolpopexy as compared to just 50 milliliters within the da Vinci patient cohort.
作者報告,開腹薦骨陰道固定術與達文西薦骨陰道固定術的手術時間中位數分別為 166 分鐘與 212 分鐘。估計失血量方面,開腹薦骨陰道固定術平均為 150 毫升,而達文西患者組僅為 50 毫升。
Length of stay for the da Vinci group averaged two days as compared to three days for the open sacrocolpopexy group. However, 48% of the women treated within the da Vinci group experienced a length of stay of less than 24 hours as compared to just 1% for the women undergoing an open sacrocolpopexy.
達文西組的平均住院天數為 2 天,相較之下開腹薦骨陰道固定術組為 3 天。然而,達文西組有 48% 的女性住院時間少於 24 小時,而接受開腹薦骨陰道固定術的女性僅有 1%。
The median direct cost reported for the da Vinci group was $6668 as compared to $7804 for the open group. The overall cost reported for the robotics group was $9725 as compared to $12,485 for the open sacrocolpopexy group, with similar re-admission rates at 30 days postop. The author stated that while da Vinci sacrocolpopexy took a slightly -- took slightly longer to perform than an open sacrocolpopexy, both the direct and indirect cost for the da Vinci sacrocolpopexy was less than for open sacrocolpopexy.
達文西組報告的直接成本中位數為 6,668 美元,相較於開腹組的 7,804 美元。機器人組報告的總成本為 9,725 美元,相較於開腹薦骨陰道固定術組的 12,485 美元,且術後 30 天再入院率相近。作者表示,雖然達文西薦骨陰道固定術的施作時間略—略長於開腹薦骨陰道固定術,但達文西薦骨陰道固定術的直接與間接成本均低於開腹薦骨陰道固定術。
This concludes my remarks and I will now turn the time over to Calvin.
以上為我的發言,接下來把時間交給 Calvin。
Calvin Darling - Senior Director of Finance
Calvin Darling - Senior Director of Finance
Thank you, Aleks. I will be providing you with our financial forecast for 2013 including procedures, revenues and other elements of the income statement on a GAAP basis. I will also provide estimates of significant non-cash expenses to provide you with visibility into our expected future cash flows.
謝謝你,Aleks。我將提供我們 2013 年的財務預測,包括手術量、營收以及依 GAAP 基礎編製之損益表的其他項目。我也會提供重大非現金費用的估計,讓各位更清楚我們預期未來的現金流。
Starting with procedures, in 2013 we expect procedure growth to be driven by US gynecology, US general surgery and international dVP procedures. We expect our 2013 total procedures to grow approximately 20% to 23% from the base of approximately 450,000 procedures performed in 2012.
先從手術量談起,2013 年我們預期手術量成長將由美國婦科、美國一般外科以及國際 dVP 手術所帶動。我們預期 2013 年總手術量將較 2012 年約 450,000 例的基期成長約 20% 至 23%。
Based on an increasing proportion of benign, short-term elective procedures in our procedure mix we anticipate a more pronounced quarterly seasonality impact in 2013 as compared to 2012, resulting in proportionally lower Q1 and Q3 procedure volumes and proportionally higher Q4 volumes.
由於我們的手術組合中良性、短期的選擇性手術占比提高,我們預期 2013 年的季度季節性影響將較 2012 年更為明顯,導致第 1 季與第 3 季手術量相對較低,而第 4 季手術量相對較高。
Moving on to revenues, in 2013 we expect to achieve annual revenue growth of between 16% and 19%. We expect typical capital sales seasonality in 2013 with the proportion of full year system units sold in each quarter to follow a pattern fairly consistent with 2012. We would expect fewer systems to be sold in the upcoming seasonally slower first quarter than in the recently completed seasonally stronger fourth quarter. As a result, total first-quarter 2013 revenue is likely to be lower than the fourth quarter of 2012.
接著談營收,2013 年我們預期可達成年營收成長 16% 至 19%。我們預期 2013 年資本設備銷售將呈現典型的季節性,各季度售出的全年系統台數占比將遵循與 2012 年相當一致的模式。我們預期在即將到來、季節性較淡的第一季,系統銷售台數將少於剛結束、季節性較旺的第四季。因此,2013 年第一季總營收很可能低於 2012 年第四季。
All 2013 revenues, particularly capital sales, are subject to the impact of economic conditions.
2013 年所有營收,特別是資本設備銷售,均可能受到經濟狀況的影響。
Now turning to operating income. Our full-year 2012 operating income was 40.3% of revenue. In 2013, as we reviewed on our last call, the medical device tax has become effective. Based upon our 2012 regional and product mix, we would estimate the tax to equate to roughly 1.1% of our consolidated revenue.
接下來談營業利益。我們 2012 年全年的營業利益為營收的 40.3%。如同我們在上次電話會議中所回顧的,2013 年醫療器材稅已開始生效。依據我們 2012 年的區域與產品組合,我們估計該稅負約相當於合併營收的 1.1%。
We plan to record the expense as a component of cost of sales, thus impacting both gross and operating profit margins. We also expect the impact of new products to shift our overall gross margin percentage slightly lower in 2013.
我們計畫將該費用記錄為銷貨成本的一部分,因此將影響毛利率與營業利益率。我們也預期新產品的影響將使我們2013年的整體毛利率百分比略為下降。
In addition, we expect to continue to invest in field sales and training resources to support procedure adoption. Based upon these factors we expect our 2013 operating income to fall within a range of between 38% and 39% of revenue.
此外,我們預期將持續投資於外勤銷售與訓練資源,以支持手術採用。基於這些因素,我們預期2013年營業利益將落在營收的38%至39%之間。
Consistent with prior years, we would expect our operating income as a percentage of revenue to be lower in the first quarter of 2013, reflecting system sales and procedure seasonality. 2013 operating expenses should follow a quarterly growth pattern similar to 2012, with Q1 reflecting the full quarter impact of our Q4 new hires.
與往年一致,我們預期2013年第一季的營業利益占營收比重將較低,反映系統銷售與手術量的季節性。2013年營業費用應會呈現與2012年類似的季度成長型態,其中第一季將反映我們第四季新進人員的整季影響。
We expect our non-cash stock compensation charges to increase from $153 million recorded in 2012 to approximately $184 million to $192 million in 2013. Amortization of purchased intellectual property, which is mostly recorded as R&D expense, is expected to increase from $23 million in 2012 to $28 million to $30 million in 2013.
我們預期非現金股票酬勞費用將由2012年認列的1.53億美元增加至2013年約1.84億至1.92億美元。外購智慧財產權攤銷(多數列為研發費用)預期將由2012年的2,300萬美元增加至2013年的2,800萬至3,000萬美元。
Other income, which is mainly comprised of interest income, was approximately $16 million in 2012. We expect other income to grow to between $18 million and $22 million in 2013.
其他收入主要由利息收入構成,2012年約為1,600萬美元。我們預期2013年其他收入將成長至1,800萬至2,200萬美元之間。
With regard to income tax, on our last call we had estimated a 2013 income tax rate of between 29% and 31% of pretax income. Now, including the impact of the reinstatement of the R&D tax credit for 2013, we anticipate our base full-year tax rate to fall within a range of between 28% and 30% of pretax income.
關於所得稅,在上次電話會議中我們估計2013年所得稅率為稅前所得的29%至31%。現在,納入2013年研發稅額抵減恢復的影響後,我們預期全年基礎稅率將落在稅前所得的28%至30%之間。
As Marshall mentioned we expect to recognize a discrete benefit of between $6 million and $8 million during the first quarter of 2013 related to the reinstatement of the 2012 R&D tax credit. This discrete item will result in a downward adjustment of our Q1 2013 income tax expense from the 28% to 30% full-year rate.
如Marshall所提,我們預期在2013年第一季認列一筆與2012年研發稅額抵減恢復相關的一次性利益,金額約為600萬至800萬美元。此一次性項目將使我們2013年第一季所得稅費用相較於全年28%至30%的稅率向下調整。
We estimate our share count for calculating EPS in Q1 2013 will be approximately 41.2 million shares.
我們估計2013年第一季用於計算每股盈餘(EPS)的加權平均股數約為4,120萬股。
That concludes our prepared remarks. We will now open the call for your questions.
以上為我們預先準備的發言。接下來我們將開放提問。
Operator
Operator
(Operator Instructions). Lennox Ketner, Bank of America.
(接線員指示)。美國銀行(Bank of America)的Lennox Ketner。
Lennox Ketner - Analyst
Lennox Ketner - Analyst
Congratulations on a good quarter. I guess first, I just wanted to touch base on general surgery and the growth that you're seeing in cholecystectomies. I am wondering, at this point in the year, if it is possible to speak either quantitatively or qualitatively to how much of that uptake you think is trialing versus sticky procedures.
恭喜本季表現不錯。我想先就一般外科以及你們在膽囊切除術(cholecystectomies)所看到的成長做個確認。我想請教,在今年這個時間點,是否可能以量化或質化方式說明,你們認為這些採用中有多少屬於試用(trialing),又有多少屬於可持續、黏著度高的手術量(sticky procedures)。
I don't know if you can give any sense as to what percentage of the 450 customers that have bought Single-Site kits have bought second kits, or if it is possible to speak at all to how much you think is trialing versus sticky procedures.
我不確定你們是否能提供一些概念,例如購買Single-Site套件的450家客戶中,有多少比例已購買第二套,或是否能談談你們認為其中有多少是試用、多少是黏著度高的手術量。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think it is really too early to say what is a trend, what is alternately a long-term expectation. It is our belief, and what we can say at this point -- and it is our belief that with 450 US customers purchasing starter kits, that there is a lot of interest in people moving toward single incision surgery.
我認為現在要判斷什麼是趨勢、或什麼可視為長期預期,仍然太早。我們目前能說的是——也是我們的看法——在美國有450家客戶購買入門套件,顯示大家對朝向單切口手術的移動有很高的興趣。
Trying to define how many of those we will have going forward that are part of the initial purchases is difficult to say. But I think we are most pleased with the fact that it is indeed a large number of US customers that are going through the purchasing activity and actually doing these procedures today.
要界定其中有多少在未來會延續、以及有多少只是初期採購的一部分,確實很難說。但我們最感到欣慰的是,確實有大量美國客戶正在進行採購活動,而且今天就已經在做這些手術。
Lennox Ketner - Analyst
Lennox Ketner - Analyst
Okay, and then just as a follow-up, there was some concern around the recent AAGL statement regarding robotic hysterectomies, and the fact that the AAGL doesn't believe it should be used to replace laparoscopic hysterectomies. I know that most of your hysterectomy procedures that are being done right now are actually replacing open surgeries, but I am wondering if you made the just frame for people to go forward basis what percentage of the hysterectomy market you think is still being done as open procedures, just so people have a sense as to what the remaining opportunity is there just in terms of simply converting open procedures to robotics.
好的,接著追問一下,近期AAGL針對機器人子宮切除術的聲明引發一些疑慮,AAGL認為不應用它來取代腹腔鏡子宮切除術。我知道你們目前多數子宮切除術其實是在取代開腹手術,但我想請教,你們是否能為大家建立一個往後評估的基準:你們認為子宮切除市場中仍有多少比例是以開腹方式進行,讓大家了解剩餘機會有多大——也就是單純把開腹手術轉換為機器人手術的空間。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
You are right. I think many of the studies that were cited in the AAGL statement actually compared robotic surgery to laparoscopic surgery, and really failed to recognize that the majority of robotic cases would have probably previously been done via laparotomy.
你說得沒錯。我認為AAGL聲明中引用的許多研究其實是將機器人手術與腹腔鏡手術相比較,卻未能真正認知到,多數機器人案例在過去很可能是透過剖腹(laparotomy)來完成。
We had, as you recall, as we had gone through our sizing, if you will, of our target market, we have talked about this pretty specifically over the years. When we started really with the da Vinci hysterectomy, I think it was estimated that somewhere along the lines of 66% of the hysterectomies performed in the United States were being performed through laparotomy.
如你所記得的,在我們對目標市場進行規模估算時,多年來我們一直相當具體地談過這點。當我們真正開始推動達文西子宮切除術(da Vinci hysterectomy)時,當時估計美國約有66%的子宮切除術是透過剖腹手術進行。
I believe the Solucient database, which is a division of Thomson Reuters, I think in their most recent publication, I think goes through 2011, they estimated that only 39% of the procedures in the United States, now, the hysterectomy procedures, are being performed through a laparotomy. Vaginal, I think, was something like 14%. Laparoscopy was around 16% and the remainder was through da Vinci.
我相信Solucient資料庫(Thomson Reuters旗下部門)在其最新出版物中(我想資料涵蓋至2011年)估計,目前美國子宮切除術中只有39%是透過剖腹手術進行。陰道途徑(vaginal)我記得大約是14%。腹腔鏡約為16%,其餘則是透過達文西完成。
So, our objective really is to move these complex procedures from open, invasive incisions to minimally invasive surgery, and I believe that the record shows that is taking place.
因此,我們的目標確實是將這些複雜手術從開放式、侵入性切口轉向微創手術,而我相信紀錄顯示這件事正在發生。
Lennox Ketner - Analyst
Lennox Ketner - Analyst
Okay, thanks very much. I will let someone else hop in.
好的,非常感謝。我讓其他人接著問。
Operator
Operator
Ben Andrew, William Blair.
William Blair的Ben Andrew。
Ben Andrew - Analyst
Ben Andrew - Analyst
Two questions for me. First, can you talk about the adoption curve that you have seen in gen surg so far? And if you adjust for the installed base change, how it compares to maybe dVH most appropriately?
我有兩個問題。第一,能否談談你們目前在一般外科所看到的採用曲線(adoption curve)?以及如果調整已裝機基礎(installed base)的變化後,與可能最適合比較的dVH相比,情況如何?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
It is interesting in general surgery versus let's say dVH, as we are talking about a category. Within the in general surgery category, if I'm not mistaken, there have been somewhere around 40-plus procedures that have gone into the category of general surgery that have been done -- performed with da Vinci.
一般外科相較於例如dVH,作為一個「類別」來談其實很有意思。在一般外科這個類別之內,如果我沒記錯,已經有大約40多種手術被歸入一般外科類別,並且已使用達文西來執行——也就是已經完成的手術。
So it is difficult to really compare apples to apples between a category and, let's say, something like dVH, which is a single procedure. And it is even more difficult comparing it to, let's say, dVP, which is a single procedure that is always done for a single disease, which is cancer. In other words, there is just too many inconsistencies between the three.
因此,要在一個「類別」與例如dVH這種單一手術之間做真正的同類比較(apples to apples)其實很困難。而若拿它與例如dVP相比就更困難,因為dVP是單一手術,且永遠是針對單一疾病——癌症——所進行。換句話說,這三者之間不一致之處太多。
But what we will say is, within the category of general surgery, the two procedures that are driving a great deal of that growth are cholecystectomy and colon surgery. Not just low interior resection, but right colons, left colons, transverse colons, et cetera.
但我們可以說的是,在一般外科類別中,推動大量成長的兩項手術是膽囊切除術與結腸手術。不僅是低位前切除(low anterior resection),也包括右半結腸、左半結腸、橫結腸等等。
Ben Andrew - Analyst
Ben Andrew - Analyst
And, Aleks, can you talk a little bit about the typical experience for a new general surgeon starting out in -- wanting to do single Single-Site chole or whatever. Is there a typical kind of process they go through and how quickly people are coming up that curve?
另外,Aleks,你能否談談一位新的普外科醫師剛開始、想做單孔(Single-Site)膽囊切除或其他手術時的典型經驗?他們通常會經歷怎樣的流程?以及大家在那條學習曲線上提升的速度如何?
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
A lot of that depends on what their experiences going into that case. In other words, are they completely laparoscopically trained? Are they laparoscopically naive? Are they robotically trained, robotically naive? And I think each one of those is a little bit different.
其中很大一部分取決於他們在進入那個案例之前的經驗。換句話說,他們是否接受過完整的腹腔鏡訓練?他們是否對腹腔鏡不熟悉?他們是否接受過機器人手術訓練、或對機器人手術不熟悉?我認為這幾種情況各自都有些不同。
But I would say that, by and large, you will have people that will do multi-incision cholecystectomies with the traditional da Vinci system, or they will do some other procedures prior to moving into the single incision surgeries. I don't know that I can say that there is a typical profile and/or a typical experience.
但我會說,總體而言,很多人會先用傳統的達文西系統做多切口膽囊切除術,或是在轉向單切口手術之前先做一些其他手術。我不確定我能說存在一個典型的輪廓和/或典型的經驗。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay, and then just maybe a quick question for Marshall. Can you talk a little bit about the expectations on guidance? And specifically thinking about Europe, if you have guided to the 20% to 23% procedure growth, does that give you 25% US and 15% Europe or international more broadly? Just characterize for us what you have built in there, please, thanks.
好的,接著可能給 Marshall 一個簡短問題。你能談談對指引(guidance)的預期嗎?特別是從歐洲的角度來看,如果你們指引的是手術量成長 20% 到 23%,那是否意味著美國 25%、歐洲或更廣義的國際 15%?請幫我們描述一下你們在其中納入了哪些假設,謝謝。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
We haven't broken it down. And, you know, we have given you a range because there is some uncertainty associated with certain elements of the guidance itself. And so I'm not going to break it down into the details.
我們沒有把它拆分。而且你知道,我們給了你一個區間,因為指引本身的某些要素存在一些不確定性。所以我不會把它拆解到細節層面。
Ben Andrew - Analyst
Ben Andrew - Analyst
All right, thank you.
好的,謝謝。
Operator
Operator
David Lewis, Morgan Stanley.
David Lewis,摩根士丹利。
David Lewis - Analyst
David Lewis - Analyst
Aleks, I wonder if you could tell us maybe in the back half of 2012 or for all of 2012, you think about total general surgery procedures, either in terms of adoption curve steepness, either in Single-Site chole versus LAR, where you're seeing a steeper relative adoption curve or where the contribution to growth is stronger?
Aleks,我想請你談談也許在 2012 年下半年或整個 2012 年,你們看總體一般外科手術量時,從採用曲線的陡峭程度來看,無論是單孔膽囊(Single-Site chole)相較於 LAR,你們看到哪一個的相對採用曲線更陡,或是哪一個對成長的貢獻更強?
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
It is too early to say. As you know, with adoption curves, it is dangerous to try to project steepness too early in the equation. So, trying to really pull out an individual point today and draw a lot of conclusions from it is probably dangerous.
現在下結論還太早。如你所知,對採用曲線而言,在方程式很早期就去推估陡峭程度是有風險的。所以,試圖在今天抓出單一個點並從中得出很多結論,可能是有風險的。
But in terms of overall growth cholecystectomy is, as we have said, I think, in our previous call, it is our third largest overall procedure. And that is all of cholecystectomy, including Single-Site and four-incision cholecystectomy. So that one would be growing at a steeper rate.
但就整體成長而言,膽囊切除術如同我們所說的,我想在之前的電話會議也提過,它是我們第三大的整體手術項目。而那包含所有膽囊切除術,包括 Single-Site 以及四切口膽囊切除術。因此那一項會以較陡的速度成長。
David Lewis - Analyst
David Lewis - Analyst
Okay, very helpful. And then, Marshall, just a quick question on margins. It sounds like some of the dynamic is mixed with some of your higher growth procedures coming in, and maybe a slightly lower GM. How much of that is simply temporary?
好的,非常有幫助。接著,Marshall,關於毛利率一個簡短問題。聽起來其中一些動態與你們成長較快的手術項目占比提高、以及可能略低的毛利率(GM)混在一起。其中有多少只是暫時性的?
When you start getting real scale advantages back half 2013 into 2014, does that sort of vanish when you get back to a corporate gross margin for consumables that is more appropriate? Or are we always went to see some sort of a drag here, just based on how you're pricing some of these individual units?
當你們在 2013 年下半年到 2014 年重新取得真正的規模優勢時,這種情況是否就會消失,並回到一個更符合公司層級的耗材毛利率?還是說我們總會看到某種拖累,僅僅是基於你們對某些個別單元的定價方式?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
It is the -- variation in margin really have to do with the introduction of new products, and the margins that are earned on these new products. Initially you're dealing with low volumes. You're dealing with maybe not optimized manufacturing and design.
毛利率的變動主要與新產品的導入,以及這些新產品所能取得的毛利率有關。一開始你面對的是低出貨量。你也可能面對尚未最佳化的製造與設計。
Those products are -- we work on reducing those costs over time, increasing the volumes and reducing those costs over time. But some of those products are more complex than the products we have had in the past, and so it is not practical to predict that they will actually get to the same level of margin as, let's say, a simple product that we have.
這些產品——我們會隨時間推進來降低成本、提高出貨量並隨時間降低成本。但其中一些產品比我們過去的產品更複雜,因此不太實際去預測它們最終會達到與例如我們某些簡單產品相同的毛利率水準。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Some improve quickly in margin, and some take a greater investment and longer time to improve.
有些產品的毛利率改善很快,而有些則需要更大的投入、也需要更長時間才能改善。
David Lewis - Analyst
David Lewis - Analyst
Okay, thank you very much.
好的,非常感謝。
Operator
Operator
Tycho Peterson, JPMorgan.
Tycho Peterson,摩根大通。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Question, may be first one on dVP, your sequential performance was a little bit better than we did modeling. I know you're somewhat reluctant to call the bottom here, but can you talk about whether there is any change in your own expectations from the peak to trough drop-off in dVP? And is it too early to start to think about some of those that have dropped out coming back in for surgery?
問題,可能先問 dVP,你們的季比表現比我們模型預估的稍微好一些。我知道你們對於在這裡判定已觸底有些保留,但你能談談你們自己對 dVP 從高峰到谷底下滑幅度的預期是否有任何改變嗎?以及現在是否還太早去思考那些已經退出的病患會回來接受手術?
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
I think as you started out in your question, I think you accurately stated the way we feel about it. It is too early for us to call. 90 days have passed since the last time we talked, and we've have watched it a little closer. We have seen a favorable Q4, recognizing that Q3 is historically a seasonally slower quarter. And so I think trying to draw too many conclusions at this stage is probably not in anyone's best interest.
我想如你在問題一開始所說,你很準確地描述了我們的感受。我們現在下判斷還太早。距離上次我們談到這件事已經過了 90 天,我們也更密切地觀察了一下。我們看到第四季表現較為有利,同時也認知到第三季歷來是季節性較慢的一季。因此我認為在這個階段試圖得出太多結論,可能不符合任何人的最佳利益。
So I can say that we didn't see a great deal of difference other than the numbers in terms of the discussions with the physicians. I think people are pretty much in the same place today as they were in Q3. However, the numbers have shown an improvement, and we will watch it and we will see when we feel safe -- when it feels safe to call a trough.
所以我可以說,除了數字本身之外,我們在與醫師的討論中並沒有看到很大的差異。我認為大家今天的狀態大致與第三季相同。不過,數字顯示有所改善,我們會持續觀察,並在我們覺得安全——在感覺可以安全判定谷底時——再做判斷。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
And then in terms of the quarter, in terms of placements, are you able to call out the impact of the VA order at all? We have had a few people asking about that.
另外就本季而言,就裝機(placements)來看,你們能否說明一下 VA 訂單的影響?我們有幾位投資人一直在問這件事。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
The VA contract was for about $34 million of product. That was a contract for both systems, initial stocking of instruments and accessories, as well as other things that go with it, like simulator. And we did ship the majority of what was under that contract in the last quarter.
VA 合約大約是 3,400 萬美元的產品。那是一份涵蓋系統、初始器械與配件備貨,以及其他相關項目(例如模擬器)的合約。而我們在上一季已出貨了該合約項下的大部分內容。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Okay. And then just last one, as we think about full ramp of the stapler here, I know you are still kind of in the trialing period and working with KOLs. But when should we think about that moving into full commercial launch?
好的。最後一個問題,當我們思考這款縫合器(stapler)的全面放量時,我知道你們仍處於試用期並與 KOL 合作。但我們應該在什麼時候預期它會進入全面商業化上市?
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
We will be advancing it carefully the first half of this year and likely through the full year. So in the first half we expect to be out in customers in this first quarter. And we will advance it slowly as we get the customer feedback and really make sure that we have optimized their experience.
我們會在今年上半年謹慎推進,並很可能貫穿全年。因此在上半年,我們預期第一季就會在客戶端開始使用。我們會在取得客戶回饋後逐步推進,並確保我們已最佳化他們的使用體驗。
So this will be a conservative launch, really focused on the fact that stapling is subtle, and we want to make sure that our customers are having great experiences.
因此這將是一個保守的上市策略,重點在於縫合(stapling)是很細微的,我們希望確保客戶有很好的使用體驗。
Tycho Peterson - Analyst
Tycho Peterson - Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
Larry Keusch, Raymond James.
Larry Keusch,Raymond James。
Larry Keusch - Analyst
Larry Keusch - Analyst
Aleks, maybe you could talk a little bit about prostate and the experience in Europe. I guess there had been some concern that some of the changes in the US here would have a pronounced effect over there. So, any thoughts on that would be great.
Aleks,也許你可以談談前列腺手術以及在歐洲的經驗。我想之前有人擔心美國這邊的一些變化會在那邊產生明顯影響。所以,如果你有任何看法會很棒。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
I think, as we have said in the past, the world is getting smaller. Information is shared quickly. And there are -- the same census, if you will, of participants at both national and international meetings. So I think there is some effect. And it is -- in some markets it is probably felt a little bit more than in others.
我想,如同我們過去所說,世界正在變得更小。資訊分享得很快。而且——如果你願意這麼說——在國內與國際會議上,參與者的組成是相同的。所以我認為確實會有一些影響。而且——在某些市場,這種影響可能比其他市場感受得更明顯一些。
In other words, in a place like Japan where you're starting relatively new, there is a lot of growth ahead of us. And you were probably powering through that, any concerns, if there were some concerns, about whether or not PSA screening is appropriate or conservative treatment, whereas in other countries it is probably a little bit more pronounced.
換句話說,在像日本這樣相對較新的市場,我們前方仍有很大的成長空間。而你們可能一直在推進這件事;若有疑慮,可能是關於 PSA 篩檢是否合適或採取保守治療;但在其他國家,這種情況可能更為明顯。
So I don't know that we can necessarily label Europe homogeneously and believe -- or international, for that matter, and believe that it is something that resembles -- each country resembles the next. But I think there are probably some markets where it is a little bit more pronounced than others.
所以我不確定我們是否能把歐洲一概而論——或就此而言把國際市場一概而論——並認為它像是某種彼此相似、每個國家都像下一個國家的樣子。但我認為確實有些市場比其他市場更為明顯。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Like in the US; it is a hard thing to model.
像在美國;這是一件很難建模的事。
Larry Keusch - Analyst
Larry Keusch - Analyst
Got it. And then just two other quick ones, just relative to the [five-time] clearance that you guys are anticipating for Firefly in biliary. Could you talk about how important that is to push the adoption of Single-Site chole? It seems to me that obviously if you can reduce common bile duct injuries, that would be a positive with that technology.
了解。另外還有兩個很快的問題,關於你們預期 Firefly 在膽道方面取得的 [五次] 核准(clearance)。你能談談這對推動單孔膽囊切除(Single-Site chole)的採用有多重要嗎?在我看來,顯然如果能降低總膽管損傷,那對這項技術會是正面的。
And then, separately, I think last quarter you provided some feel for, in the US, what procedures grew if you were to adjust for the declines in prostatectomy. I was wondering if you could help us with that in the fourth quarter.
另外,分開來問,我記得上季你們提供了一些看法:在美國,如果把前列腺切除術下降的影響調整掉,哪些手術量是成長的。我想請你們也幫我們看一下第四季的情況。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Just speaking to the first one, the 510(k) submission for Firefly biliary imaging, that has just been submitted this quarter, so in terms of when we expect a clearance, no endpoint to tell you about yet.
先回應第一個問題,Firefly 膽道影像的 510(k) 送件是在本季才剛提交,所以就我們預期何時取得核准而言,目前還沒有可以告訴你的明確時間點。
We do think that biliary imaging in real time is interesting and meaningful for cholecystectomy for the reason that you indicate. A common bile duct injury is a serious complication, and we think that Firefly can augment the white light imaging and be a compliment to cholangiography, so that is the intent. We have just started that conversation with FDA, and as it proceeds and we have something more material to share, we will.
我們確實認為即時膽道影像對膽囊切除術很有趣且具意義,原因正如你所指出的。總膽管損傷是嚴重的併發症,我們認為 Firefly 可以強化白光影像,並作為膽道造影(cholangiography)的補充,這就是其用意。我們才剛開始與 FDA 進行這方面的討論;隨著進展、若有更具體可分享的內容,我們會再更新。
With regard to the breakouts on the adjustments and the procedure mix, I will turn to Aleks Cukic.
至於調整後的拆分與手術組合,我把問題交給 Aleks Cukic。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
Yes, I think it is pretty consistent with what I had mentioned earlier in terms of hysterectomy, cholecystectomy, colon rectal surgery and endometriosis resection, partial nephrectomy. Those procedures are the ones that I think primarily are the strength for the quarter and for the year.
是的,我認為這與我先前提到的相當一致,包括子宮切除術、膽囊切除術、結直腸手術與子宮內膜異位切除、部分腎切除術。我認為這些手術是本季以及全年主要的強項來源。
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
Yes. And just looking at the numbers on a full-year basis, dVP on a full-year basis was down 15%, as Aleks described in his notes. If you back that out in the US, everything else was up about 39%.
是的。另外從全年數字來看,正如 Aleks 在他的說明中所描述,全年 dVP 下降了 15%。如果在美國把這部分扣除,其他所有項目大約成長了 39%。
Larry Keusch - Analyst
Larry Keusch - Analyst
Thanks so much.
非常感謝。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
David Roman - Analyst
David Roman - Analyst
I certainly echo in the comments earlier on a very strong quarter here. So congrats, nice way to start -- end the year and start 2013.
我也呼應先前的評論,這一季表現非常強勁。所以恭喜你們,這是結束今年並展開 2013 年的好方式。
But want just to focus a little bit on the general surgery application, and more specifically, if you can give some perspective on where the procedure you're doing are coming from, and I guess really what I am asking is -- are these procedures ever done is a laparoscopic setting? Were they done open? Are these people who wouldn't otherwise do the procedures? Are you adding growth to the market? Maybe just any perspective you can give us on the competitive modalities would be helpful.
但我想稍微聚焦在一般外科的應用上,更具體地說,如果你們能提供一些觀點:你們正在做的這些手術量是從哪裡來的?我真正想問的是——這些手術以前是否曾在腹腔鏡環境下進行?以前是開腹做的嗎?這些是原本不會做這些手術的人嗎?你們是在為市場帶來新增的成長嗎?也許你們能就競爭性替代方式提供任何觀點,對我們都會有幫助。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
Yes, I think, again, we believe -- we talked about 42,000 procedures, up from 15,000 in 2011. If you look at the biggest contributor there, it is cholecystectomy. And almost all of those procedures had been done laparoscopically, because the standard of care is laparoscopic cholecystectomy. So, that one, I think is fairly simple to say where it is coming from.
是的,我想再次強調,我們提到大約 42,000 例手術,較 2011 年的 15,000 例增加。如果看最大的貢獻來源,是膽囊切除術。而幾乎所有這些手術原本就是以腹腔鏡進行,因為照護標準就是腹腔鏡膽囊切除。所以這一項,我認為相對容易說明它是從哪裡來的。
If you look at bowel surgery, and specifically large bowel or colon, you have left colons. Well, you have -- well, you start on the other side. You have right colons, transverse, lap, sigmoid, moving down into the rectum and then you have total colectomy. Depending on which procedure -- each of those are counted as a different procedure.
如果看腸道手術,特別是大腸或結腸,你有左側結腸。嗯,你有——嗯,從另一側開始說。你有右側結腸、橫結腸、腹腔鏡、乙狀結腸,往下到直腸,然後還有全結腸切除。視乎是哪一種手術——這些每一項都會被算作不同的手術。
Depending on which of those procedures you're talking about, if you did it inversely and you started at the most difficult or the lowest penetrated, laparoscopically, it would be low rectal cancer. There you're talking about -- data would suggest that it is single-digit penetration of laparoscopy, whereas if you're talking about right colon it is double-digit, and I have seen numbers perhaps as high as 20%, or 21% or 22% that is laparoscopic.
取決於你談的是哪一種手術;如果反過來看、從最困難或腹腔鏡滲透率最低的開始,那會是低位直腸癌。那裡你談到的是——資料顯示腹腔鏡的滲透率是個位數;而如果談右側結腸則是雙位數,我看過的數字可能高到 20%、21% 或 22% 是以腹腔鏡進行。
So you have a range of where those patients would have gone, either to open surgery or a laparoscopic surgery. And then you have a smattering of procedures that range from some open -- that would have been done open, whether it would be distal pancreatectomy or liver surgery. And then you have other procedures such as Nissens that may have been done laparoscopically.
所以這些病人可能會去的地方有一個範圍:要嘛是開腹手術,要嘛是腹腔鏡手術。然後你還有一些零星的手術,範圍涵蓋某些原本會以開腹進行的——例如遠端胰臟切除或肝臟手術。另外也有其他手術,例如 Nissen(胃底折疊術)可能原本就是以腹腔鏡進行。
So there is a lot of movement that is going on, which is, I think it was an earlier question that Ben had asked about general surgery. You have what amounts to, I think, 40-some procedures that have been done. And trying to build an individual profile for general surgery is a challenge.
所以有很多正在發生的轉移;我想這也呼應 Ben 先前問到的一般外科問題。你們實際上做了大約 40 多種手術。而要為一般外科建立一個個別的輪廓(profile)是有挑戰的。
David Roman - Analyst
David Roman - Analyst
And then maybe as a follow-up on the guidance, obviously 20% to 23% procedure guidance, is a solid number. If I look at that contrasted with the total revenue guidance, it does imply a fairly sharp slowing on the system side of the business. Anything particular to call it there? Is it comps? Is it lapping the Japan reimbursement? Or anything to help us understand why that business would start -- would slow to the degree that the guidance implies?
接著可能追問一下你們的指引(guidance)。顯然 20% 到 23% 的手術量指引是很不錯的數字。如果我把它和總營收指引對照來看,這似乎意味著系統端業務會相當明顯地放緩。這裡有什麼特別原因嗎?是比較基期(comps)嗎?是因為日本給付(reimbursement)效應已經過了一輪(lapping)嗎?或有任何資訊能幫助我們理解,為什麼該業務會開始——會放緩到指引所暗示的程度?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
I am not sure that the conclusion is absolutely right. There are a lot of factors in the guidance, including the average selling prices of the systems and the procedures and so on. So I don't necessarily agree with the conclusion.
我不確定這個結論是否完全正確。指引中有很多因素,包括系統與手術的平均售價(ASP)等等。所以我不一定同意這個結論。
Aleks Cukic - VP of Strategy
Aleks Cukic - VP of Strategy
So I think we have lived in a good world of good mix on systems. And so I'm not sure that we believe that that system mix and that ASP will hold for the whole year. I think on the I&A front, as we move out in time, as we have always said, as stocking orders will become a smaller part of the picture, and have less impact, and so we would see some level of pressure on pricing, on I&A.
我想我們一直處在一個系統組合(mix)相當不錯的環境。因此我們不確定是否認為這樣的系統組合與 ASP 能維持一整年。我認為在 I&A(儀器與配件)方面,隨著時間推進,正如我們一貫所說,備貨訂單(stocking orders)會在整體中占比變小、影響也會降低,因此我們會在 I&A 的定價上看到某種程度的壓力。
And I think in general, I think we have shown over the years procedure growth does outpace the procedure -- procedure growth outpaces revenue growth, because of -- systems have not -- generally are not at the same level.
而且我想整體而言,這些年我們已經顯示手術量成長會快於營收成長,因為——系統端通常不會在同一個水準上。
David Roman - Analyst
David Roman - Analyst
Okay, and then, lastly, just to clarify on the share count. I think you said 41.2 million shares. Was that a comment regarding the first quarter or the full year of 2013?
好的,最後,想釐清一下股數。我想你說的是 4,120 萬股。那是指第一季的數字,還是 2013 全年的數字?
Marshall Mohr - SVP and CFO
Marshall Mohr - SVP and CFO
That is the first quarter comment.
以上是第一季的評論。
David Roman - Analyst
David Roman - Analyst
Okay. Got it. Thank you.
好的。了解。謝謝。
Operator
Operator
Rick Wise, Stifel Nicolaus.
Rick Wise,Stifel Nicolaus。
Rick Wise - Analyst
Rick Wise - Analyst
If you could just give us a little more color on some of the structural changes you are making in Europe; Gary you indicated that your make a significant progress as you have deepened the organization. Just a couple of things. How long do you envision this investment, maybe extraordinary investment process continuing?
如果可以的話,能否請您再多談一些您們在歐洲正在進行的結構性變革;Gary,您提到隨著組織深化,已取得顯著進展。我有幾點想問。您預期這項投資、也許是較為特殊的投資流程,還會持續多久?
And maybe give us a little more details about some of the specific actions, if you could, that you're taking place, and maybe how you are approaching the market or pan-Europe or Company-specific. Anything to understand a little better some of the things that are happening there. Thank you.
另外,如果可以的話,能否再提供一些更具體的行動細節,例如您正在採取哪些措施,以及您是以泛歐洲市場的角度,還是以各公司/各國市場為主來推進。任何能讓我們更了解那邊正在發生什麼的資訊都很有幫助。謝謝。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think with regard to the progress we have made, I think we have made some progress. I am not ready to call it significant progress yet.
我想就我們已取得的進展而言,我認為確實有一些進展。但我還不準備稱之為「顯著進展」。
I think that our investments have really been in three areas. One has been getting the right sales reps in the right territories; pretty straightforward. We have done that and we will continue to do so, and that runs on a set of coverage metrics and market analyses that are pretty straightforward.
我認為我們的投資主要集中在三個領域。第一是把合適的業務代表配置到合適的區域;這相當直接。我們已經做了,也會持續這麼做;這是依據一套相當明確的覆蓋率指標與市場分析來運作。
We have been making some more targeted investments. This is not cast of thousands, but in terms of understanding reimbursement and regulatory and the resources that are required to perform in different markets, and so that has been a more targeted set of investments. And we have invested in some better topline leadership, and I think investments in all three of those are encouraging. But they're early.
我們也做了一些更有針對性的投資。這不是大規模擴編,而是著重於了解各市場的給付(reimbursement)與法規,以及在不同市場要成功所需的資源,因此這是一組更聚焦的投資。此外,我們也投資於更強的營收端(topline)領導力;我認為這三方面的投資都令人鼓舞。但仍處於早期階段。
I think that we will continue to invest for the next several quarters. It isn't huge dollar value investments. They are more targeted in that way. But they are important. And so far I think that we've made the right first steps. I think we need to continue on that pathway.
我認為接下來幾個季度我們會持續投資。這些投資金額並不巨大。而是以更有針對性的方式投入。但它們很重要。到目前為止,我認為我們已踏出正確的第一步。我們需要沿著這條路徑繼續走下去。
Rick Wise - Analyst
Rick Wise - Analyst
Thank you for that. And you would think that the major thrust is completed this year or by midyear or just, again, any sense of timing?
謝謝您的說明。那您認為主要的推進工作會在今年完成、或在年中前完成嗎?還是說,能否再給我們一些時間點的概念?
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think we will be concentrating on it through the year, and about this time next year, we ought to ask that same set of questions.
我認為我們會在今年全年都把重點放在這件事上;而大約到明年的這個時候,我們應該再問同樣一組問題。
Rick Wise - Analyst
Rick Wise - Analyst
Okay (multiple speakers)
好的(多位發言者)
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Just time for one more question, if you will.
如果可以的話,我們只剩下一個問題的時間。
Rick Wise - Analyst
Rick Wise - Analyst
Okay. Japan, just again, I think you said significant demand. And with the da Vinci Si approval in hand, is this going to be an incremental driver? Are we going to see more upgrades maybe in 2013? Again, help frame that for us. Thank you.
好的。日本方面,再確認一下,我想您提到需求相當強勁。那在已取得 da Vinci Si 核准的情況下,這會成為額外的成長驅動因素嗎?我們是否會在 2013 年看到更多升級(upgrades)?請再幫我們建立一下框架。謝謝。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
I think there is really two things to say with regard to Si approval in Japan. The first one is we are excited about the approval, in large part because it allows us to bring to Japan, with follow-on clearances, a set of technologies that we think have really made a benefit in the rest of the world. And -- things like Single-Site and Firefly and vessel sealing, dual console and simulator, a bunch of things that we have invested on the Si system side. So we are excited about that.
我認為關於日本的 Si 核准,主要有兩點要說。第一,我們對核准感到振奮,很大一部分原因是它讓我們能在後續核准(follow-on clearances)之後,把一系列我們認為已在世界其他地區帶來實質效益的技術帶到日本。例如單孔(Single-Site)、Firefly、血管封合(vessel sealing)、雙控制台(dual console)與模擬器(simulator)等,這些都是我們在 Si 系統端投入的多項技術。因此我們對此感到興奮。
I think structurally, though, in the longer term the Japanese market penetration will be paced by additional procedure reimbursement. And so, near-term, it's a great thing to get in the hands of the Japanese customer. We need to continue to work on reimbursements beyond prostatectomy, and we will continue to do so.
不過從結構面來看,長期而言,日本市場的滲透率將取決於更多手術項目的給付(reimbursement)。因此短期內,能把它交到日本客戶手上是一件很棒的事。我們需要持續推動前列腺切除術(prostatectomy)以外的給付項目,我們也會繼續努力。
Rick Wise - Analyst
Rick Wise - Analyst
Thank you so much.
非常感謝。
Gary Guthart - President and CEO
Gary Guthart - President and CEO
Thank you. That was our last question. As we have said previously, while we focus on financial metrics such as revenues, profits and cash flow during these conference calls, our organizational focus remains at increasing patient value, and by improving surgical outcomes and reducing surgical trauma.
謝謝。以上是我們最後一個問題。如同我們先前所說,雖然在這些電話會議中我們會聚焦於營收、獲利與現金流等財務指標,但我們組織的重點仍在於提升病患價值,並透過改善手術結果與降低手術創傷。
I hope the following experience from Warren in California gives you some sense of what this means in the lives of our patients. Quote -- last year I made a donation to the Sutter Maternity & Surgery Center for the da Vinci product. I had no idea that someday I might benefit by the use of this system. Having an electrical engineering background, I am interested in innovations that benefit people. I considered this system to be a must-have tool for our surgical centers.
我希望接下來來自加州 Warren 的經驗,能讓各位感受到這對病患生活的意義。引述——去年我為 Sutter 產科與手術中心捐款購置 da Vinci 產品。我完全沒想到有一天我自己可能會因使用這套系統而受益。由於我有電機工程背景,我對能造福人群的創新很感興趣。我認為這套系統是我們手術中心必備的工具。
A few months ago after successive urine samples showed traces of blood, my nurse practitioner urged me to see a urologist. Dr. Joe Franks discovered a small cancer in my bladder which he removed on May 8, 2012. A follow-up CT scan on May 25 showed a tumor in my left kidney. Because I am 88, I was considered borderline for surgery, and if the mass appeared to be stable, I might be lucky enough to outlive the tumor.
幾個月前,在連續的尿液樣本顯示有血跡後,我的護理師(nurse practitioner)敦促我去看泌尿科醫師。Joe Franks 醫師在我的膀胱發現一個小型癌症,並於 2012 年 5 月 8 日將其切除。5 月 25 日的追蹤 CT 掃描顯示我的左腎有一個腫瘤。因為我已 88 歲,被認為處於手術邊緣適應症;如果腫塊看起來穩定,我或許有機會在腫瘤之前先走完人生。
Such was not to be. By late July, I was passing visible blood in my urine. On August 1, Dr. Franks agreed we should go ahead with surgery if my internist gave the okay. On Friday, August 3, the internist pronounced me to be fit and I was on the list for surgery.
但事情並非如此。到了 7 月下旬,我的尿液中出現肉眼可見的血。8 月 1 日,Franks 醫師同意,如果我的內科醫師允許,我們就應該進行手術。8 月 3 日(週五),內科醫師判定我適合手術,我也被排入手術名單。
On Saturday Dr. Franks called me to say there was a surgery cancellation for that Monday morning, August 6, using the new da Vinci system. I eagerly accepted.
週六,Franks 醫師打電話告訴我,因為有一台手術取消,我可以在週一早上(8 月 6 日)使用新的 da Vinci 系統進行手術。我欣然接受。
Dr. Franks said that all my stars must have been an alignment, as the procedure only took about two hours, not counting the admissions procedure. The next day I walked out of the hospital without having to take any pain medication, much easier than a root canal. Without da Vinci the hospital stay would have been several days. End quote.
Franks 醫師說,我一定是諸事順遂、時機完美,因為手術本身大約只花了兩個小時(不含入院流程)。隔天我就走出醫院,完全不需要服用任何止痛藥,比做根管治療還輕鬆。如果沒有 da Vinci,我可能需要住院好幾天。引述結束。
Patients like Warren are the strongest advocates for a da Vinci surgery and form the very foundation of our operating performance. We have built our Company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference.
像 Warren 這樣的病患,是 da Vinci 手術最有力的倡議者,也構成我們營運表現的根本基礎。我們打造公司,是為了讓手術超越人手的極限;我向各位保證,我們仍致力於推動那少數真正能帶來改變的關鍵事項。
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in three months.
今天的電話會議到此結束。感謝各位在這段改善手術的非凡旅程中參與並支持我們;我們期待三個月後再與各位交流。
Operator
Operator
Ladies and gentlemen, that concludes your conference for today. Thank you for your participation and for using AT&T Executive Teleconference service. You may now disconnect.
各位女士、先生,今天的電話會議到此結束。感謝各位的參與,以及使用 AT&T Executive Teleconference 服務。您現在可以掛線。